Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss drug Wegovy.
Novo Nordisk blames middlemen in U.S. healthcare system for high prices of weight loss drugs Wegovy and Ozempic
Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs led by U.S. Senator Bernie Sanders.
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novo blames US health system after criticism over Wegovy price, Bloomberg reports
Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - after rebates and fees paid to middlemen in the United States, according to a Bloomberg report on Tuesday.
Novo Nordisk: Considerable Growth Beyond Ozempic
Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo Nordisk has a long-term growth strategy, focusing on the development of new treatments for cardiovascular diseases, Alzheimer's, Parkinson's, and other emerging markets.
Where Will Novo Nordisk Be in 10 Years?
Novo Nordisk has been a dominant stock lately thanks to Ozempic, and to a lesser extent, Wegovy. The weight-loss market will, however, get a lot more crowded over the next 10 years.
Wegovy users have less kidney-related health problems, analysis of Novo study finds
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.
US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients
A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar.
Ozempic cuts kidney-disease risks, research finds
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed results from a late-stage trial presented on Friday.
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
The U.S. Food and Drug Administration's (FDA) staff on Wednesday pointed to "notable imbalance" in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk's long-acting weekly insulin.
Novo Nordisk weight loss drugs still showing upside risk - analyst
Novo Nordisk (NYSE:NVO) A/S' weight loss drug rollout continues to offer scope for upside surprises, Citi analysts have said. Despite ongoing supply constraints, four-week rolling prescription growth for the company's GLP-1-based drugs has soared, analysts said on Monday.
